This is a first-in-human, open-label, nonrandomized, two-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides immune checkpoint blockade of PD-L1 as well as conditional T cell co-stimulation through 4-1BB agonism for localized immune stimulation.
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||January 30, 2019||Phase 1||Interventional|
Primary Outcome 1 - Measure: Frequency of adverse events of INBRX-105
Primary Outcome 1 - Time Frame: Up to 2-3 years
Primary Outcome 2 - Measure: Severity of adverse events of INBRX-105
Primary Outcome 2 - Time Frame: Up to 2-3 years
Primary Outcome 3 - Measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-105
Primary Outcome 3 - Time Frame: Up to 2-3 years
- Part 1 (escalation): Patients with locally advanced or metastatic non-resectable solid
tumors, Hodgkin or Non-Hodgkin lymphoma whose disease has progressed despite standard
therapy and for whom no further standard therapy exists, or who refuse available
standard treatment options.
- Part 2 (expansion cohorts): Patients with non-small cell lung cancer, melanoma, and
PD-L1 basket cohort consisting of head and neck squamous cell carcinoma, gastric or
gastro-esophageal junction adenocarcinoma, renal cell carcinoma, or urothelial
(transitional) cell carcinoma, with locally advanced or metastatic, non-resectable
disease, which has progressed despite standard therapy or for whom no standard or
clinically acceptable therapy exists.
- Refractory or relapsed to anti-PD-1 or anti-PD-L1, and anti-CTLA4 if applicable (NOTE:
Only for tumor types, for which these checkpoint inhibitors are FDA approved).
- PD-L1 positivity by immunohistochemistry (IHC). Part 1 (escalation) PD-L1 positivity
is not required. Expansion cohorts: Combined Positive Score (CPS) or Tumor Proportion
Score (TPS) ≥ 5%.
- Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 for Part 1
and ECOG PS of 0, 1 or 2 for Part 2.
- Prior exposure to 4-1BB agonists.
- Receipt of any investigational product or any approved anticancer drug(s) or
biological product(s) within 4 weeks prior to the first dose of study drug.
Exceptions: Hormone replacement therapy, testosterone, or oral contraceptives. NOTE:
Previous exposure to anti-PD-L1 checkpoint inhibitor requires a minimum washout period
of 24 weeks prior to the first dose of study drug.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, and multiple myeloma) other
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent
malignancy whose natural history or treatment does not have the potential to interfere
with the safety or efficacy assessments of INBRX-105.
- Known or active primary central nervous system (CNS) tumors, leptomeningeal disease
and CNS metastases. Exception: Subjects with previously treated, asymptomatic, and
clinically stable CNS metastases may be allowed study entry if certain criteria apply.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation
of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required
systemic steroids or other immunosuppressive medications. Certain exceptions as
defined in protocol apply.
- Treatment with systemic immunosuppressive medications within 4 weeks prior to the
first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
for Part 1. Exceptions as defined in protocol for expansion cohorts will apply.
- History of hepatitis or cirrhosis (e.g., non-alcohol steatohepatitis, alcohol or
drug-related, autoimmune, hepatitis B, or hepatitis C) for Part 1. Exceptions as
defined in protocol for expansion cohorts will apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or
pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction,
uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart
disease < 3 months; left ventricular ejection fraction (LVEF) < 50%; New York Heart
Association (NYHA) Class III or IV congestive heart failure; or uncontrolled
hypertension. Active, hemodynamically significant pulmonary embolism within 3 months
prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first
dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC)
or bone marrow (BM) transplantation.
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Klaus Wagner, MD, PhD
Role: Study Director
Affiliation: Inhibrx, Inc.
Name: Kirsti Cook, VPClinOps
|HonorHealth Research Institute
Scottsdale, Arizona 85258
Grand Rapids, Michigan 49546
San Antonio, Texas 78229